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ABSTRACT
Background: The National Institute for Health and
Care Excellence (NICE) Technology Appraisal Guidance
on spinal cord stimulation (SCS) was published in
2008 and updated in 2012 with no change. This
guidance recommends SCS as a cost-effective
treatment for patients with neuropathic pain.
Objective: To assess the impact of NICE guidance by
comparing SCS uptake in England pre-NICE (2008–
2009) and post-NICE (2009–2012) guidance. We also
compared the English SCS uptake rate with that of
Belgium, the Netherlands, France and Germany.
Design: SCS implant data for England was obtained
from the Hospital Episode Statistics (HES) database
and compared with other European countries where
comparable data were available.
Results: The HES data showed small increases in SCS
implantation and replacement/revision procedures, and
a large increase in SCS trials between 2008 and 2012.
The increase in the total number of SCS procedures
per million of population in England is driven primarily
by revision/replacements and increased trial activity.
Marked variability in SCS uptake at both health regions
and primary care trust level was observed.
Conclusions: Despite the positive NICE
recommendation for the routine use of SCS, we found
no evidence of a significant impact on SCS uptake in
England. Rates of SCS implantation in England are
lower than many other European countries.
INTRODUCTION
The National Institute for Health and Care
Excellence (NICE) is a Department of Health
(DH) funded arms-length body, established
in 1999 to principally reduce ‘the postcode
lottery’, that is the variation in the availability
and quality of National Health Service (NHS)
treatments and care in England and Wales.1 2
NICE publishes various types of guidance
including Technology Appraisals (TA),
Clinical Guidelines, Quality Standards and
Interventional Procedures Guidance.2 The
TA guidance is based on evaluations of clin-
ical and cost-effectiveness of selected tech-
nologies. The NHS is legally obliged to
provide funding for medicines and treat-
ments recommended within 3 months of the
guidance.1 In December 2011, the DH
announced in its Innovation, Health and
Wealth report that commissioners are
expected to provide access to new treatments
within 90 days of approval.1 3
The NICE TA guidance 159 on Spinal Cord
Stimulation (SCS) for chronic pain of neuro-
pathic or ischaemic origin was published in
October 2008 and reviewed in January 2012
when no changes were made.4 This TA guid-
ance approves SCS for adults with continued
chronic neuropathic pain (measuring at least
50 mm on 0–100 mm visual analogue score)
for at least 6 months despite all standard con-
ventional treatment and after undergoing a
successful trial of SCS by a multidisciplinary
team.4
We examined the data for SCS uptake in
England between 2008 and 2012 in order to
assess the impact of NICE TA guidance
implementation. We compared this to the
SCS implant rate in other European coun-
tries. Data were also requested from all
Primary Care Trusts (PCT) via a Freedom of
Strengths and limitations of this study
▪ This study contributes a novel data analysis in
the area of spinal cord stimulation, which high-
lights a lack of uptake of a cost-effective technol-
ogy within the National Health Service (NHS).
▪ Our findings are based on data extracted from
the Hospital Episodes Statistics database which
relies on hospital-coded data on procedures and
indications.
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Information request with regard to their SCS commis-
sioning policy to determine whether a policy around the
implementation of NICE guidance was in place or
whether Individual Funding Requests (IFR) were being
used.
METHODS
Data for pre-NICE (2008–2009) and post-NICE (2009–
2010; 2010–2011; 2011–2012) TA 159 publication for
SCS procedural activity were obtained from the Hospital
Episode Statistics (HES) database,5 using the QUANTIS
system via NHiS.6 The HES is a national statistical data
warehouse for England of the care provided by NHS
hospitals. QUANTIS is a database of NHS and social
care numerical data for the UK, and NHiS is a vendor
that provides subscribed access to the QUANTIS
database.
We examined OPCS-4 procedure codes A48.3
(implantation of neurostimulator adjacent to the spinal
cord), A48.4 (attention to neurostimulator adjacent to
the spinal cord) and A48.7 (insertion of neurostimulator
electrodes into the spinal cord). The OPCS code A48.3
was assumed to reﬂect new permanent SCS implants,
code A48.4 to contain both replacements and revisions,
and code A48.7 to represent trial procedures. OPCS
code 48.4 does not allow for a clear differentiation
between battery replacement and revisions.
The relevant SCS codes were ﬁltered by indication to
ensure that only back pain and spinal indications were
included. This eliminated any inclusion of other types of
neurostimulation that may have been miscoded, for
example, for bowel and bladder indications. SCS uptake
results are expressed per million populations across each
Strategic Health Authority regions in England. We also
compared uptake rates across PCT.
Oracle (11g Database) and Excel (Microsoft Ofﬁce
2010 Pro) software programs were utilised for the data
analysis. We compared English SCS uptake data from
2011 to 2012 (code A48.3 only) with European countries
where we were able to source the appropriate equivalent
data, that is France, Belgium, Germany and the
Netherlands.7
RESULTS
The HES data analysis for the year 2008–2012 showed a
small increase in procedure codes 48.3 and 48.4 (table 1)
and large increase in procedure code 48.7. Figure 1 illus-
trates the activity trends for each separate procedure
code. On analysis of each of the procedure codes, the
increase in SCS procedures appears to be driven primar-
ily by replacements, revisions and a large increase in trial
activity. There was considerable variation in the rate of
SCS uptake across Strategic Health Authorities through-
out this time horizon. The breakdown of the number of
SCS procedures funded by PCTs in 2011–2012 is shown
in ﬁgure 2, indicating considerable inequity of patient
access to this NICE-approved treatment.
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Table 2 compares the available European data against
procedure code 48.3, reﬂecting the number of new SCS
implants only. In France there was a small increase in
the number of SCS implants per million of population
for the period 2008–2010 (table 2). The rate of uptake
of SCS per million of population in England is the
lowest compared with these other European countries
(table 2).
Figure 3 shows requested data from all PCT with
regard to their SCS commissioning policy via a Freedom
of Information request. The response rate was 60.9%,
with 40.2% of PCTs requiring IFR, 18.5% following a
Specialised Commissioning Group (SCG) policy, 15.2%
following either PCT policy or with no active policy, and
only 10.8% following the NICE TA Guidance allowing
automatic funding. While the level of data did not allow
a statistical analysis of the correlation between the PCT
policy status and the number of SCS procedures funded,
some evidence of an association between regions with
an existing policy and the number of patients being
funded for SCS was apparent. For example, across
Yorkshire and the Humber, where a clear SCG policy
was being followed by the collective PCTs, a high rate of
SCS procedures was observed at 33.2 cases per million
(table 1). This was also evident with the East of England
(29.8 procedures per million). Conversely, the lowest
rates of SCS referrals were reported in regions with no
PCT or SCG policy in place, such as the West Midlands
and London (7.9 and 9.4 procedures per million,
respectively).
DISCUSSION
The NHS has a mandatory duty to fund and provide
NICE-approved treatments recommended within a NICE
TA within 90 days. However, our UK data analysis from
2008 to 2012 shows that the NICE TA 159 had a small
impact on uptake of SCS in neuropathic pain. Although
an increase of 19.3% in SCS procedures was observed
over the 4-year period, ﬁgure 4 includes battery replace-
ments and revisions in addition to new SCS permanent
implants. When new SCS implants are considered alone,
Figure 1 Breakdown of spinal cord stimulation procedural
activity trends (procedure codes A48.3, A48.4 and A48.7).
Figure 2 Number of total spinal
cord stimulation procedures per
Primary Care Trusts in 2011–
2012.
Table 2 Comparison of new SCS implants in the UK
(procedure code A48.3 only) against other European
countries per year
Yearly SCS/million
Country 2008 2009 2010 2011
Belgium 84.6
France 9.19 8.17 11.35
The Netherlands 54.3
Germany 11.7
UK (England) 11 10.7
SAS, spinal cord stimulation; SCS, spinal cord stimulation.
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an increase in uptake of only 12.4% was observed
between 2008 and 2012 (ﬁgure 1), despite the NICE TA
159 advocating a 10% increase in uptake each year.
Interestingly the substantial rise in procedure code 48.7
(trial procedures) does not appear to convert into a
comparable increase in permanent SCS procedures.
Given that the conversion rate of trial to permanent SCS
implants is generally consistent at around 75–80%,8
accuracy in provider coding in this instance may be
questioned.
There remains a considerable regional inequality in
patient access to this NICE approved treatment. The
Right Care9 is one of the national work streams in the
DH Quality Innovation Productivity and Prevention pro-
gramme which identiﬁes unwarranted variation in NHS
treatments based on geographical areas.9 10 One of the
Right Care objectives for 2011–2012 is to minimise this
unwarranted variation and maximise value.9 Value can
be increased by improving quality, optimising resource
utilisation and ensuring that patients receive appropriate
interventions.
Our ﬁndings are in contrast with a NICE implementa-
tion report11 that shows a generally effective impact of
guidance for surgical procedures. For example, laparo-
scopic colorectal surgeries occurred at higher rate than
forecasted by NICE (TA 105).12 Laparoscopic inguinal
hernia repair uptake increased following guidance, but
it stabilised at lower levels than that NICE forecasted
(TA 83).13 In addition, there was overall increase in bar-
iatric surgery for morbid obesity following NICE guid-
ance (CG 43).14 Our study provides data on the marked
variability in rate of SCS uptake at both health authority
and PCT level.
NICE assessed SCS as a highly cost-effective treatment
for failed back surgery syndrome with an incremental
£10 480 per quality adjusted life year (QALY) ratio com-
pared with conventional medical management alone,
and £9219 per QALY gained when compared with
repeat back operation.4 These ratios are considerably
below the UK willingness to pay threshold of £20 000 to
30 000 per QALY.
Despite mandatory TA guidance on SCS, the majority
of PCTs required IFR for each patient (ﬁgure 3). Some
PCTs rated SCS as a low priority procedure. The reasons
for the barriers to funding are multifactorial and
include lack of awareness of SCS referral guidelines, lack
of NICE TAG enforcement at regional and national
level, as well as a limitation of clinical capacity at
implanting centres. Owing to the limitations of the avail-
able data, it is not possible to disentangle the factors
responsible for the continuing inequity of funding for
SCS implants. Yet we can comment that there has been
no signiﬁcant increase in the number of implanting
centres. The capacity within existing centres is not
showing a growth curve as expected in response to the
NICE guidance. Only 10.8% of PCTs implemented
NICE guidance as a funding policy (ﬁgure 3). It is pos-
sible that piecemeal funding and the difﬁculties asso-
ciated with such an approach, as well as the impact of
the marked regional variations, have prevented the
expansion of current providers. The reported incidence
of failed back surgery syndrome is estimated as 10–40%
of patients undergoing back surgery.15 In a recent survey
of the UK, 53% of pain clinics estimated 10% of their
referrals comprising failed back surgery syndrome
patients and the remaining 47% of pain clinics esti-
mated it as 20–30% of their referrals, therefore lack of
candidates is unlikely.16
In a comparison to France, Germany, Belgium and
the Netherlands, England has the lowest rate of implants
per million of the population. Smaller countries show a
much higher rate of SCS implants,7 with Belgium and
the Netherlands implanting 84.6 and 54.3 per million of
population, respectively. Nevertheless, for Belgium and
the Netherlands only 1 year data are available; therefore,
Figure 3 Data from Freedom of Information request
regarding Primary Care Trusts policies on spinal cord
stimulation (data accessed 2011).
Figure 4 Number of spinal cord stimulation implanting
centres year-on-year.
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we are unable to comment on trends. Data for France
were available for the past 3 years (table 2) which show
no signiﬁcant increase in SCS implants. The main indi-
cations for SCS are similar across the four countries, that
is failed back surgery syndrome or radicular pain,
phantom pain, peripheral nerve injury, traumatic bra-
chial plexus injury, spinal lesion, diabetic polyneurop-
athy and postherpetic neuralgia.7 Focusing on the most
common indication for SCS of failed back surgery syn-
drome, it is estimated that 10–40% of patients undergo-
ing spinal surgery will develop neuropathic pain.15
According to the HES database, the number of spinal
surgery procedures in England in 2009–2010 was
117 803.17 Assuming that one-third of these procedures
is being carried out for pain, the annual estimate will be
78 533 procedures of which 10–40% (7853–31 414)
would be expected to be eligible for SCS treatment.16
Based on these data, less than 2% of the eligible popula-
tion of neuropathic patients in England are currently
receiving SCS treatment. A lack of awareness of SCS as a
clinical and cost-effective treatment option among refer-
ring physicians may be hindering the uptake of this
NICE-approved technology. More constructive engage-
ment with the wider population of patients and referring
physicians by the neuromodulation community are war-
ranted to ensure appropriate and early referral for SCS
therapy.
CONCLUSION
Our study shows that the NICE TA 159 has had negli-
gible impact on the uptake of SCS for new patients, and
rates of SCS implantation were highly variable across
Strategic Health Authorities and PCTs. The reasons for
the lack of impact appear to be multifactorial and may
include limited awareness of SCS as a clinical and cost-
effective treatment option among the wider referral
community. Within the new arrangements of NHS
England, where SCS is deemed to be a prescribed spe-
cialised service that will be commissioned centrally,
some of these barriers may be addressed including a
shift towards more equitable access to this technology,
and elimination of the use of IFRs. Future implementa-
tion of NICE Innovation Scorecards to track compliance
with NICE TA and other NICE compliance initiatives
may further help to reinforce and track the implementa-
tion of NICE guidance.
Contributors All authors had an integral role in producing this manuscript
and have made substantial contributions to the analysis and interpretation of
data, drafting and revision of the article and approving the final version of the
manuscript.
Funding Access to the QUANTIS database to extract the relevant Hospital
Episode Statistics data was funded by Medtronic UK.
Competing interests RST is a paid consultant for Medtronic Inc. Sam Eldabe
has previously undertaken consulting work for Medtronic Inc.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Readers are invited to contact NH, if they wish to
request any raw unpublished Hospital Episodes Statistics data pertaining to
the manuscript.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/3.0/
REFERENCES
1. Sorenson C, Drummond M, Kanavos P, et al. National Institute for
Health and Clinical Excellence (NICE): how does it work and what
are the implications for the U.S.? 2008 (updated April 2008). http://
www.npcnow.org/issuearea/ebm.asp
2. NICE. How we work (updated 13 July 2012). http://www.nice.org.uk/
aboutnice/howwework/how_we_work.jsp
3. DOH. Creating change: innovating health and wealth one year on.
Health Do, 2011.
4. NICE. Technology Appraisal Guidelines 159: spinal cord stimulation
for chronic pain of neuropathic or ischaemic origin, 2008 (updated
Oct 2008). http://www.nice.org.uk/TA159
5. Hospital Episode Statistics (cited 2013). http://www.hesonline.nhs.
uk/
6. NHiS. http://www.nhis.info/
7. Camberlin C, San Miguel L, Smit Y, et al. KCE Report 189C: Health
Technology Assessment. Neuromodulation for the management of
chronic pain: implanted spinal cord stimulators and intrathecal
analgesic delivery pumps. In: Centre BHCK, editor. Brussels, 2012.
8. North RB. SCS trial duration. Neuromodulation 2003;6:4–5.
9. NHS Rightcare 2013 (updated 2013). http://www.rightcare.nhs.uk/
resources
10. NHS Rightcare Atlas 2013 (cited 4 April 2013). http://www.rightcare.
nhs.uk/atlas
11. N.I.C.E. NICE implementation programme, 2012 (updated 14
November 2012). http://www.nice.org.uk/usingguidance/
niceimplementationprogramme/nice_implementation_programme.jsp
12. NICE. NICE implemention uptake report: laparoscopic surgery for
colorectal cancer. NICE Technology Appraisal 105. Excellence
NIoHaC, ed. 2010.
13. NICE. Laparoscopic surgery for inguinal hernia repair: implementation
uptake report. Technology appraisal 83. Excellence NIfHaC, ed. 2004.
14. N.I.C.E. Obesity guidance on the prevention, identification,
assessment and management of overweight and obesity in adults
and children. Clinical Guidance CG43. Excellence NIfHaC, ed. 2006.
15. Thomson S, Jacques L. Demographic characteristics of patients with
severe neuropathic pain secondary to failed back surgery syndrome.
Pain Pract 2009;9:206–15.
16. Tharmanathan P, Adamson J, Ashby R, et al. Diagnosis and
treatment of failed back surgery syndrome in the UK: mapping of
practice using a cross-sectional survey. Br J Pain 2012;6:142–52.
17. Mailis-Gagnon A, Furlan AD, Sandoval JA, et al. Spinal cord
stimulation for chronic pain. Cochrane Database Syst Rev 2004;(3):
CD003783.
Vyawahare B, Hallas N, Brookes M, et al. BMJ Open 2014;4:e004182. doi:10.1136/bmjopen-2013-004182 5
Open Access
